Yasuhiro Tsume
Overview
Explore the profile of Yasuhiro Tsume including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsume Y, Ashworth L, Bermejo Sanz M, Cicale V, Dressman J, Fushimi M, et al.
Mol Pharm
. 2024 Sep;
21(10):5315-5325.
PMID: 39311714
Biorelevant dissolution and its concept have been widely accepted and further developed to meaningfully predict the bioperformance of oral drug products. Biorelevant methodologies have been applied to design and optimize...
2.
Naing M, Tsume Y
Eur J Pharm Biopharm
. 2024 Aug;
203:114436.
PMID: 39111581
The poor water solubility of orally administered drugs leads to low dissolution in the GI tract, resulting to low oral bioavailability. Traditionally, in vitro dissolution testing using the compendial dissolution...
3.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, et al.
AAPS J
. 2023 Jun;
25(4):58.
PMID: 37291273
No abstract available.
4.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, et al.
AAPS J
. 2023 Apr;
25(3):45.
PMID: 37085637
Assessing in vivo performance to inform formulation selection and development decisions is an important aspect of drug development. Biopredictive dissolution methodologies for oral dosage forms have been developed to understand...
5.
Tsume Y
Drug Metab Pharmacokinet
. 2023 Mar;
50:100502.
PMID: 37001300
This article reviews the impacts on the in vivo prediction of oral bioavailability (BA) and bioequivalence (BE) based on Biopharmaceutical classification systems (BCS) by the food-drug interaction (food effect) and...
6.
Hens B, Seegobin N, Bermejo M, Tsume Y, Clear N, McAllister M, et al.
AAPS J
. 2022 Jan;
24(1):17.
PMID: 34982285
The present work aimed to differentiate between in vitro dissolution profiles of ibuprofen as input for GastroPlus™ and to see the impact on systemic exposure. In vitro dissolution profiles of...
7.
Gonzalez-Alvarez I, Bermejo M, Tsume Y, Ruiz-Picazo A, Gonzalez-Alvarez M, Hens B, et al.
Pharmaceutics
. 2021 Apr;
13(4).
PMID: 33917118
The purpose of this study was to predict in vivo performance of three oral products of Etoricoxib ( as reference and two generic formulations in development) by conducting in vivo...
8.
Tsume Y, Patel S, Wang M, Hermans A, Kesisoglou F
J Pharm Sci
. 2020 Sep;
109(11):3471-3479.
PMID: 32888960
The physiological pH changes and peristalsis activities in gastrointestinal (GI) tract have big impact on the dissolution of oral drug products, when those oral drug products include APIs with pH-dependent...
9.
Bermejo M, Hens B, Dickens J, Mudie D, Paixao P, Tsume Y, et al.
Pharmaceutics
. 2020 Jan;
12(1).
PMID: 31963448
The application of in silico modeling to predict the in vivo outcome of an oral drug product is gaining a lot of interest. Fully relying on these models as a...
10.
Bermejo M, Kuminek G, Al-Gousous J, Ruiz-Picazo A, Tsume Y, Garcia-Arieta A, et al.
Pharmaceutics
. 2019 Mar;
11(3).
PMID: 30884755
The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol...